Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors

被引:12
作者
Faivre, Sandrine J. [1 ]
Olszanski, Anthony J. [2 ]
Weigang-Koehler, Karin [3 ]
Riess, Hanno [4 ]
Cohen, Roger B. [5 ]
Wang, Xuejing [6 ]
Myrand, Scott P. [6 ]
Wickremsinhe, Enaksha R. [6 ]
Horn, Candice L. [6 ]
Ouyang, Haojun [6 ]
Callies, Sophie [6 ]
Benhadji, Karim A. [7 ]
Raymond, Eric [1 ,8 ]
机构
[1] Beaujon Univ Hosp, Dept Med Oncol, Clichy, France
[2] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[3] Paracelsus Med Univ, Med Klin 5, Nurnberg, Germany
[4] Charite Campus Virchow Hosp, Dept Med, Div Hematol Oncol & Tumor Immunol, Berlin, Germany
[5] Univ Penn, Perelman Sch Med, Div Hematol Oncol, Philadelphia, PA 19104 USA
[6] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA
[7] Lilly France, Med Oncol, Neuilly Sur Seine, France
[8] Hosp Beaujon, F-92118 Clichy, France
关键词
Oral gemcitabine prodrug; Phase I study; Pharmacokinetics; Pharmacogenomics; Solid tumors; COMBINATION; PLASMA;
D O I
10.1007/s10637-015-0286-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background This Phase-I-study aimed to determine the recommended Phase-II-dosing-schedule of LY2334737, an oral gemcitabine prodrug, in patients with advanced/metastatic solid tumors. Pharmacokinetics, cytokeratin-18 (CK18) levels, genetic polymorphisms, and antitumor activity were additionally evaluated. Methods Patients received escalating doses of LY2334737 either every other day for 21 days (d) followed by 7 days-drug-free period (QoD-arm) or once daily for 7 days every other week (QD-arm). The 28 days-cycles were repeated until disease progression or unacceptable toxicity. Standard 3 + 3 dose-escalation was succeeded by a dose-confirmation phase (12 additional patients to be enrolled on the maximum tolerated dose [MTD]). Results Forty-one patients received QoD- (40-100 mg) and 32 QD-dosing (40-90 mg). On QoD, 3/9 patients experienced dose-limiting toxicities (DLTs) on the 100 mg dose (2 x G3 diarrhea, 1 x G3 transaminase increase); 1 additional DLT (G3 diarrhea) occurred during dose confirmation at 90 mg (12 patients). On QD, 1 patient each experienced DLTs on 60 mg (G3 transaminase increase) and 80 mg (G3 prolonged QTcF-interval); 2/7 patients had 3 DLTs on the 90 mg dose (diarrhea, edema, liver-failure; all G3). The MTD was established at 90 mg for the QoD-arm. Seven patients on QoD and 4 on QD achieved SD (no CR + PR). Pharmacokinetics showed a dose-proportional increase in exposure of LY2334737 and dFdC without accumulation after repeated dosing. Significant increases in CK18 levels were observed. Genetic polymorphism of the cytidine deaminase gene (rs818202) could be associated with a parts per thousand yenaEuro parts per thousand G3 hepatotoxicity. Conclusions Both schedules displayed linear pharmacokinetics and acceptable safety profiles. The recommended dose and schedule of LY2334737 for subsequent Phase-II-studies is 90 mg given QoD for 21 day.
引用
收藏
页码:1206 / 1216
页数:11
相关论文
共 24 条
[1]   A PHASE-I CLINICAL, PLASMA, AND CELLULAR PHARMACOLOGY STUDY OF GEMCITABINE [J].
ABBRUZZESE, JL ;
GRUNEWALD, R ;
WEEKS, EA ;
GRAVEL, D ;
ADAMS, T ;
NOWAK, B ;
MINEISHI, S ;
TARASSOFF, P ;
SATTERLEE, W ;
RABER, MN ;
PLUNKETT, W .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (03) :491-498
[2]   Synthesis, Crystallization, and Biological Evaluation of an Orally Active Prodrug of Gemcitabine [J].
Bender, David M. ;
Bao, Jingqi ;
Dantzig, Anne H. ;
Diseroad, William D. ;
Law, Kevin L. ;
Magnus, Nicholas A. ;
Peterson, Jeffrey A. ;
Perkins, Everett J. ;
Pu, Yangwei J. ;
Reutzel-Edens, Susan M. ;
Remick, David M. ;
Starling, James J. ;
Stephenson, Gregory A. ;
Vaid, Radhe K. ;
Zhang, Deyi ;
McCarthy, James R. .
JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (22) :6958-6961
[3]   Diagnostic and prognostic role of plasma levels of two forms of cytokeratin 18 in patients with non-small-cell lung cancer [J].
De Petris, Luigi ;
Branden, Eva ;
Herrmann, Richard ;
Sanchez, Betzabe Chavez ;
Koyi, Hirsh ;
Linderholm, Barbro ;
Lewensohn, Rolf ;
Linder, Stig ;
Lehtio, Janne .
EUROPEAN JOURNAL OF CANCER, 2011, 47 (01) :131-137
[4]   Phase 1b study of the oral gemcitabine 'Pro-drug' LY2334737 in combination with capecitabine in patients with advanced solid tumors [J].
Infante, Jeffrey R. ;
Benhadji, Karim A. ;
Dy, Grace K. ;
Fetterly, Gerald ;
Ma, Wen Wee ;
Bendell, Johanna ;
Callies, Sophie ;
Adjei, Alex A. .
INVESTIGATIONAL NEW DRUGS, 2015, 33 (02) :432-439
[5]   Determination of common genetic variants in cytidine deaminase (CDA) gene in Indian ethnic population [J].
Iyer, Sandhya N. ;
Ankala, Arunkanth ;
Singhal, Rekha S. ;
Hegde, Madhuri R. .
GENE, 2013, 524 (01) :35-39
[6]   Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors [J].
Koolen, Stijn L. W. ;
Witteveen, Petronella O. ;
Jansen, Robert S. ;
Langenberg, Marlies H. G. ;
Kronemeijer, Roelien H. ;
Nol, Annemarie ;
Garcia-Ribas, Ignacio ;
Callies, Sophie ;
Benhadji, Karim A. ;
Slapak, Christopher A. ;
Beijnen, Jos H. ;
Voest, Emile E. ;
Schellens, Jan H. M. .
CLINICAL CANCER RESEARCH, 2011, 17 (18) :6071-6082
[7]   Utilization of cytokeratin-based biomarkers for pharmacodynamic studies [J].
Linder, Stig ;
Olofsson, Maria Hagg ;
Herrmann, Richard ;
Ulukaya, Engin .
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2010, 10 (03) :353-359
[8]   Gemcitabine versus Modified Gemcitabine: A Review of Several Promising Chemical Modifications [J].
Moysan, Elodie ;
Bastiat, Guillaume ;
Benoit, Jean-Pierre .
MOLECULAR PHARMACEUTICS, 2013, 10 (02) :430-444
[9]   A User's Guide to the Encyclopedia of DNA Elements (ENCODE) [J].
Myers, Richard M. ;
Stamatoyannopoulos, John ;
Snyder, Michael ;
Dunham, Ian ;
Hardison, Ross C. ;
Bernstein, Bradley E. ;
Gingeras, Thomas R. ;
Kent, W. James ;
Birney, Ewan ;
Wold, Barbara ;
Crawford, Gregory E. ;
Bernstein, Bradley E. ;
Epstein, Charles B. ;
Shoresh, Noam ;
Ernst, Jason ;
Mikkelsen, Tarjei S. ;
Kheradpour, Pouya ;
Zhang, Xiaolan ;
Wang, Li ;
Issner, Robbyn ;
Coyne, Michael J. ;
Durham, Timothy ;
Ku, Manching ;
Thanh Truong ;
Ward, Lucas D. ;
Altshuler, Robert C. ;
Lin, Michael F. ;
Kellis, Manolis ;
Gingeras, Thomas R. ;
Davis, Carrie A. ;
Kapranov, Philipp ;
Dobin, Alexander ;
Zaleski, Christopher ;
Schlesinger, Felix ;
Batut, Philippe ;
Chakrabortty, Sudipto ;
Jha, Sonali ;
Lin, Wei ;
Drenkow, Jorg ;
Wang, Huaien ;
Bell, Kim ;
Gao, Hui ;
Bell, Ian ;
Dumais, Erica ;
Dumais, Jacqueline ;
Antonarakis, Stylianos E. ;
Ucla, Catherine ;
Borel, Christelle ;
Guigo, Roderic ;
Djebali, Sarah .
PLOS BIOLOGY, 2011, 9 (04)
[10]   Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation [J].
Patel, SR ;
Gandhi, V ;
Jenkins, J ;
Papadopolous, N ;
Burgess, MA ;
Plager, C ;
Plunkett , W ;
Benjamin, RS .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (15) :3483-3489